Phenobarbital Market Top Companies Study - Sanofi, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Phenobarbital Market- (By Indication (Epilepsy, Neonatal seizures), By Dosage Form (Tablets, Injectable, Formulations), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Phenobarbital Market is valued at US$ 1.48 Bn in 2022, and it is expected to reach US$ 2.20 Bn by 2031, with a CAGR of 4.6% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2049

Phenobarbital, a Schedule IV controlled substance with sedative and anticonvulsant properties, is widely utilized in the management of alcohol withdrawal and status epilepticus. Commonly known by its generic name or under brand names such as Luminal, phenobarbital belongs to the barbiturate class of medications. The World Health Organization (WHO) recognizes its importance and recommends its use for treating certain forms of epilepsy, particularly in resource-limited countries.

Intravenous administration of phenobarbital is typically reserved for critical medical situations. However, research indicates that induration at the infusion site can negatively affect the drug's bioavailability. To avoid the risk of withdrawal symptoms, gradual tapering is recommended when discontinuing the medication.

According to current guidelines issued by the American Epilepsy Society, phenobarbital is administered intravenously at a dose of 15 mg/kg in adults experiencing status epilepticus. With a well-established history of clinical efficacy, phenobarbital remains a primary therapeutic option for various seizure disorders, especially in low-resource settings. Its proven effectiveness continues to sustain strong demand in the global pharmaceutical market.

List of Prominent Players in the Phenobarbital Market:
• Sanofi
• Pfizer Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals
• Zydus Cadila
• Lannett Company, Inc.
• Strides Pharma Science Limited
• Cipla Ltd.
• Lupin Limited
• Aurobindo Pharma Limited
• Torrent Pharmaceuticals Ltd.
• Reddy's Laboratories Ltd.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The phenobarbital market benefits from a robust infrastructure encompassing manufacturing, distribution, and prescription networks, which ensures consistent availability across hospitals and pharmacies. This well-established framework facilitates ease of access for patients requiring anticonvulsant therapy. A key driver of market growth is the high global prevalence of epilepsy and seizure-related disorders. With millions affected worldwide, there remains a sustained demand for effective anticonvulsant medications. Phenobarbital, recognized for its long-standing clinical efficacy, continues to play a vital role in epilepsy management, particularly in regions with higher disease incidence and limited access to advanced therapeutics.

Challenges:
Despite its therapeutic benefits, phenobarbital is associated with several adverse effects, including sedation, cognitive impairment, dizziness, and behavioral disturbances. These side effects can negatively impact patient adherence and quality of life, particularly when they interfere with daily functioning or mental performance. Additionally, the risk of severe, though infrequent, adverse reactions raises important safety concerns that may influence prescribing decisions and regulatory scrutiny.

Regional Trends:
In North America, the phenobarbital market is expected to capture a significant share of global revenue and demonstrate strong growth during the forecast period. Key growth drivers include the entry of new market participants and the development of pediatric-specific formulations. Furthermore, ongoing research and development initiatives focused on enhancing the safety, efficacy, and delivery mechanisms of phenobarbital are anticipated to support market expansion. The increasing adoption of personalized treatment strategies across the region further contributes to the anticipated rise in demand for tailored phenobarbital-based therapies.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2049

Recent Developments:
• In May 2023, Mallinckrodt, Inc. introduced a new generic variety of phenobarbital pills. The medication is offered in strengths of 15 mg, 30 mg, and 60 mg, and the majority of significant insurance policies cover it.
• In January 2023, Sun Pharma launched a brand-new, extended-release phenobarbital medication. Sun Pharma Introduces SEZABYTM (phenobarbital Sodium) for the Treatment of Neonatal Seizures in the United States.

Segmentation of Phenobarbital Market-
By Indication-
• Epilepsy
• Neonatal seizures
By Dosage Form-
• Tablets
• Injectable
• Formulations
By Distribution channel-
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/phenobarbital-market/2049

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.